Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, VIC, Australia.
Department of Molecular and Translational Sciences, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, VIC, Australia.
Methods Mol Biol. 2024;2806:1-8. doi: 10.1007/978-1-0716-3858-3_1.
Patient-derived xenografts (PDXs) represent a critical advancement in preclinical cancer research, wherein human tumor samples are implanted into animal models for evaluation of therapeutic responses. PDXs have emerged as indispensable tools in translational cancer research, facilitating investigation into tumor microenvironments and personalized medicine. This chapter elucidates the historical evolution of PDXs, from early attempts in the eighteenth century to contemporary immunocompromised host models that enhance engraftment success.
患者来源异种移植(PDX)代表了临床前癌症研究的重要进展,其中人类肿瘤样本被植入动物模型中以评估治疗反应。PDX 已成为转化癌症研究中不可或缺的工具,促进了对肿瘤微环境和个性化医学的研究。本章阐述了 PDX 的历史演变,从 18 世纪的早期尝试到目前增强植入成功率的免疫缺陷宿主模型。